New Treatments
Patent Information
- Application Number
- JP2023563340
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-12-23
- Filing Date
- 2021-12-23
- Publication Date
- 2024-11-21
- Estimated Expiration
- 2041-12-23
AI Technical Summary
Current treatments for acute myeloid leukemia (AML) using bispecific antibodies targeting CD33 and CD7 receptors are inefficient and can cause myelosuppression, a severe side effect.
Development of bispecific antibodies with specific VH and VL sequences that bind to CD33 and CD7, allowing for targeted cytotoxicity in AML cells without affecting healthy bone marrow cells, thereby reducing myelosuppression.
The antibodies effectively induce cytotoxicity in AML cells while sparing healthy cells, offering an improved treatment option with reduced side effects.
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates to bispecific antibodies and antigen-binding fragments thereof that bind CD33 and CD7 for use in the treatment of hematological malignancies, in particular acute myeloid leukemia (AML). [Background technology]
[0002] Acute myelogenous leukaemia (AML), or acute myeloid leukaemia, is a heterogeneous hematological malignancy involving clonal proliferation of myeloblasts in bone marrow and peripheral blood. AML accounts for more than 90% of acute adult leukemias and is an aggressive disease with a fulminant clinical course. Despite advances in treatment regimens and current understanding of successful hematopoietic stem cell transplantation (HSCT), mortality in patients with AML remains high.
[0003] It is well known in the art that both CD7 and CD33 are internalizing cell surface antigen receptors, and that CD7 is a rapid and efficient internalizing cell surface antigen receptor (internalization is observed within 15 to 30 minutes), whereas CD33 is a slow and inefficient internalizing cell surface antigen receptor (internalization is observed after 60 minutes).
[0004] WO2019 / 102234 discloses dual targeting of cell inhibitors to cell surface receptors CD7 and CD33 in the treatment of hematological malignancies.
[0005] Based on the current state of the art and previous experimental results on monovalent CD7 and CD33 binding antibodies, it is expected that the CD33 Fab arm of a bispecific antibody is sufficient to render a bispecific antibody containing a CD33 Fab arm cytotoxic to CD33-expressing cells. Moreover, exposure of CD7-expressing cells to CD33+ / CD7+ bispecific antibodies has been shown to cause substantial cytotoxicity.
[0006] It is an object of the present invention to provide improved therapies for hematological malignancies, particularly AML. It is desirable that such therapies do not result in myelosuppression. [Prior art documents] [Patent documents]
[0007] [Patent Document 1] WO2019 / 102234 [Patent Document 2] US4,978,744 [Patent Document 3] US5,635,483 [Patent Document 4] US5,780,588 [Non-patent literature]
[0008] [Non-Patent Document 1] De Propris, MS et al. (2011) High CD33 expression levels in acute myeloid leukemia cells carrying the nucleophosmin (NPM1) mutation, haematological, 96 pp. 1548~1551 [Non-Patent Document 2] Ehninger, A. et al., (2014) Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia, Blood Cancer Journal, 4 pp. 1-10 [Non-Patent Document 3] Poeta, GD et al. (1995) CD7 Expression in Acute Myeloid Leukemia. Leuk. Lymphoma, 17, pp. 111-119 [Non-Patent Document 4] Rohrs, S. et al., (2010) CD7 in acute myeloid leukemia: correlation with loss of wild-type CEBPA, consequence of epigenetic regulation, Journal of Hematology & Oncology, 3 pp. 1-7 [Non-Patent Document 5] Rausei-Mills, V. et al., (2008) Aberrant Expression of CD7 in Myeloblasts Is Highly Associated With De Novo Acute Myeloid Leukemias With FLT3 / ITD Mutation, Am J Clin Pathol, 129 pp. 624-629 [Non-Patent Document 6] Shimamoto, T. et al. (1994) Clinical and Biological Characteristic of CD7+ Acute Myeloid Leukaemia, Cancer Genet Cytogenet 73 pp. 69-74 [Non-Patent Document 7] Reading, CL et al. (1993) Expression of unusual immunophenotype combinations in acute myelogenous leukemia, Blood 81 pp. 3083-3090 [Non-Patent Document 8] Ossenkoppele, GJ et al. (2011) Review of the relevance of aberrant antigen expression by flow cytometry in myeloid neoplasms British Journal of Haematology 153 pp. 421-436 [Non-Patent Document 9] Lo Coco, F. et al. (1989) CD7 positive acute myeloid leukaemia: a subtype associated with cell immaturity, British Journal of Haematology 73 pp. 480-485 [Non-Patent Document 10] Kita, K. et al. (1983) Clinical Importance of CD7 Expression in Acute Myelocytic Leukemia, Blood 81, pp. 2399-2405 [Non-Patent Document 11] Eto, T. et al. (1992) Biological characteristics of CD7 positive acute myelogenous leukaemia, British lournal olHaernatology 82 pp. 508-511 [Non-Patent Document 12] Chang, H. (2004) Prognostic relevance of immunophenotyping in 379 patients with acute myeloid leukemia, Leukemia Research 28 pp. 43-48 [Non-Patent Document 13] Kahl, C. et al. (2001) CD7+ and CD56+ Acute Myelogenous Leukemia is a Distinct Biologic and Clinical Disease Entity. Haematology and Blood Transfusion, 40 pp. 112-119 [Non-Patent Document 14] Tien, H. and Wang, C. (1998) CD7 Positive Hematopoietic Progenitors and Acute Myeloid Leukemia and other Minimally Differentiated Leukemia, Leukemia and Lymphoma, 3 pages 93~98
Non-patent document 15
Non-patent document 16
Non-patent document 17
Non-patent document 18
Non-patent document 19
Non-patent document 20
Non-patent document 21
Non-patent document 22
Non-patent document 23
Non-patent document 24
Non-patent document 25
Non-patent document 26
Non-patent document 27
Non-patent document 28
Non-patent document 29
Non-patent document 30
Non-patent document 31
Non-patent document 32
Non-patent document 33
Non-patent document 34
Non-patent document 35
Non-patent document 36
Non-patent document 37
Non-patent document 38
Non-patent document 39
Non-patent document 40
Non-patent document 41
Non-patent document 42
Non-patent document 43
Non-patent document 44
Non-patent document 45
Non-patent document 46
Non-patent document 47
Non-patent document 48
Non-patent document 49
Non-patent document 50
Non-patent document 51
[0009] According to a first aspect of the present invention there is provided a bispecific antibody or antigen-binding fragment thereof that binds to CD33 and CD7, the bispecific antibody having the sequence: VH SEQ ID NO: 81 and VL SEQ ID NO: 85, a first binding region that binds to human CD33, comprising a sequence having at least 95% sequence identity to and the following sequence: VH SEQ ID NO: 11, VH SEQ ID NO:21, VH SEQ ID NO:31, VH SEQ ID NO:51, VH SEQ ID NO:71, VL SEQ ID NO: 15, VL SEQ ID NO:25 VL SEQ ID NO: 35, VL SEQ ID NO:55 and VL SEQ ID NO:75 a second binding region that binds to human CD7, comprising a VH sequence and a VL sequence having at least 95% sequence identity to The present invention provides an antibody or antigen-binding fragment thereof comprising:
[0010] The sequences may have at least 98%, at least 99% or 100% sequence identity.
[0011] The second binding region that binds to human CD7 has the following sequence: a) VH SEQ ID NO:11 and VL SEQ ID NO:15; b) VH SEQ ID NO:21 and VL SEQ ID NO:25, or c) VH SEQ ID NO:31 and VL SEQ ID NO:35; The VH sequence and the VL sequence may have the following structure:
[0012] According to a further aspect, there is provided a bispecific antibody or antigen-binding fragment thereof that binds to CD33 and CD7, comprising the sequence: VH SEQ ID NO: 97 and VL SEQ ID NO: 101, a first binding region that binds to human CD33, comprising a sequence having at least 95% sequence identity to and the following sequence: VH SEQ ID NO:1, VH SEQ ID NO:51 VH SEQ ID NO:71, VL SEQ ID NO:5, VL SEQ ID NO:55 and VL SEQ ID NO:75 a second binding region that binds to human CD7, comprising a VH sequence and a VL sequence having at least 95% sequence identity to The present invention provides an antibody or antigen-binding fragment thereof comprising:
[0013] The sequences may have at least 98%, at least 99% or 100% sequence identity.
[0014] The second binding region that binds to human CD33 has the following sequence: VH SEQ ID NO: 97 and VL SEQ ID NO: 101 and VL sequences having the following structure:
[0015] According to a further aspect of the invention there is provided a bispecific antibody, or antigen-binding fragment thereof, that binds to CD33 and CD7, comprising a first binding region that binds to human CD33 and a second binding region that binds to human CD7, wherein the second binding region comprises one or more of the following: a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 13, SEQ ID NO: 23 or SEQ ID NO: 53, and / or a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 34 or SEQ ID NO: 74.
[0016] According to an additional aspect, there is provided a bispecific antibody, or antigen-binding fragment thereof, that binds to CD33 and CD7, comprising a first binding region that binds to human CD33 and a second binding region that binds to human CD7, wherein the first binding region comprises a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 100.
[0017] In accordance with yet a further embodiment, there is provided a bispecific antibody or antigen-binding fragment thereof that binds to CD33 and CD7, comprising a first binding region that binds to human CD33 and a second binding region that binds to human CD7, wherein the second binding region that binds to human CD7 is a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 12, a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 13, a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 14, a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 16, a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 17, and a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 18; b) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 22, a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 23, a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 24, a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 26, a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 27, and a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 28; c) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 32, a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 33, a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 34, a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 36, a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 37, and a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 38; d) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 52, a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 53, a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 54, a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 56, a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 57, and a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 58, and e) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 72, a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 73, a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 74, a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 76, a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 77, and a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 78; The antibody or antigen-binding fragment thereof may comprise one of:
[0018] A first binding region that binds human CD33 would preferably comprise wild-type VH CDR1, VH CDR2 and VH CDR3 and VL CDR1, VL CDR2 and VL CDR3 amino acid sequences or related sequences with two or more mutations across the CDRs of a given VH or VL chain. More preferably, a first binding region that binds human CD33 would preferably comprise wild-type VH CDR1, VH CDR2 and VH CDR3 and VL CDR1, VL CDR2 and VL CDR3 amino acid sequences or related sequences with one or more mutations across the CDRs of a given VH or VL chain.
[0019] According to a third aspect of the present invention, there is provided a bispecific antibody or antigen-binding fragment thereof that binds to CD33 and CD7, the antibody or antigen-binding fragment comprising a first binding region that binds to human CD33 comprising wild-type VH and VL sequences, and a) single or double mutations in the heavy chain, and / or b) A single mutation in the light chain A second binding region that binds to human CD7, comprising a VH sequence and a VL sequence derived from heavy and light chain sequences having at least one or more of the following: The present invention provides an antibody or antigen-binding fragment thereof comprising:
[0020] The CD7 VH and VL sequences derived from the respective heavy and light chain sequences contain the following mutations: a) single or double mutations at residues 57, 104 and 108 of the heavy chain, and / or b) A single mutation at residue 27 of the light chain The present invention may have at least one or more of the following:
[0021] Preferably, the mutation in the heavy chain would be a Gly or Lys at residue 57, or an Ala at residue 104, or an Ala at residue 108.
[0022] Preferably the mutation in the light chain would be an Ala at residue 27.
[0023] In a preferred embodiment, the second binding region that binds human CD7 comprises VH and VL sequences derived from respective heavy and light chain sequences with a single mutation at Ala at residue 104 of the heavy chain.
[0024] The antibody or antigen-binding fragment thereof described herein above with reference to any embodiment may be for use in the treatment of a CD7+CD33+ malignancy, such as a hematological malignancy.
[0025] The antibody or antigen-binding fragment thereof as described herein above with reference to any embodiment may therefore be for a method of treating a CD7+CD33+ hematological malignancy in an individual in need thereof, the method comprising administering the antibody or antigen-binding fragment thereof. The antibody or antigen-binding fragment thereof is preferably artificially produced.
[0026] In another related aspect of the invention there is provided an antibody, or antigen-binding fragment thereof, as described herein above with reference to any aspect, for use in the manufacture of a medicament for treating a CD7+CD33+ haematological malignancy.
[0027] As used herein, "medicine" refers to a substance (i.e., a drug) used in medical treatment. A medicament can be, for example, a T cell preparation for use in adoptive cell transfer.
[0028] As used herein, CD7 is preferably human CD7 and CD33 is preferably human CD33. In certain embodiments, the bispecific antibody or antigen-binding fragment thereof specifically binds to cell surface expressed CD7 and CD33. As used herein, the term "cell surface expression" refers to one or more CD7 and / or CD33 proteins expressed on the cell surface in vitro or in vivo such that at least a portion of the CD7 and / or CD33 protein is exposed to the extracellular side of the cell membrane and accessible to the bispecific antibody or antigen-binding fragment thereof of the invention.
[0029] The term "CD7+CD33+ hematological malignancies" refers to hematological malignancies characterized by the expression of both CD7 and CD33 on the surface of malignant cells (e.g., hematological malignancies that overexpress CD33 and / or CD7 on the cell surface and / or hematological malignancies that express CD33 and / or CD7 at levels that would be amenable to treatment with CD7 and an antibody or antigen-binding fragment thereof that specifically binds to CD33).
[0030] The antibody or antigen-binding fragment thereof may be capable of inducing internalization into CD33+ and / or CD7+ cells via the CD33 and / or CD7 receptors.
[0031] CD7+CD33+ hematologic malignancies include, but are not limited to, acute myeloid leukemia (AML), myelodysplastic syndromes, T-cell acute lymphoblastic leukemia, and blastic plasmacytoid dendritic cell neoplasm (BPDCN).
[0032] The antibody or antigen-binding fragment thereof bispecifically binds to CD33 and CD7, and the CD33+ and CD7+ cells are AML cells.
[0033] The antibody or antigen-binding fragment thereof may be capable of mediating antibody-dependent cellular cytotoxicity.
[0034] The antibody or antigen-binding fragment thereof may be bound to or formed with an immune effector cell. The immune effector cell may include a T cell and / or a NK cell. Preferably, the immune effector cell is a T cell. The immune effector cell may be a bispecific anti-CD33 anti-CD7 CAR-T. The T cell may include a CD33+ T cell, a CD7+ T cell, or a combination thereof.
[0035] The antibody or antigen-binding fragment thereof may comprise i) a cell-killing portion, ii) a CD7-binding portion, iii) a CD33-binding portion.
[0036] In an alternative embodiment, the CD33 and / or CD7 binding portion comprises an antigen-binding fragment of an antibody.
[0037] The cell-killing moiety may be a cytotoxin, and one skilled in the art will appreciate that a variety of cytotoxins will be compatible with the composition. The cytotoxin may be selected from: i) a peptide toxin, ii) a chemical toxin, or iii) an inhibitor of Bcl-2 or Bcl-axl, iv) an RNA polymerase inhibitor such as α-amanitin, v) a spliceosome inhibitor, vi) a microtubule targeting payload, or vii) a DNA damaging payload. The antibody or antigen-binding fragment thereof may further comprise a linking moiety that links the cell-killing moiety to the CD7 binding moiety and / or the CD33 binding moiety. The antibody or antigen-binding fragment thereof may be in the form of an antibody drug conjugate.
[0038] In bispecific antibody embodiments, such antibodies may be full-length antibodies.
[0039] Surprisingly, the inventors have discovered that bispecific antibodies comprising a CD33-binding arm and a CD7-binding arm do not cause cytotoxicity in healthy human CD33-expressing bone marrow cells, thus offering the potential for improved treatment of hematological malignancies, particularly AML, without myelosuppression.
[0040] CD7 is a pan-leucocytic receptor expressed on precursors of T cells, B lymphocytes, natural killer cells, and dendritic cells (Hao, 2001; Sempowki, 1999), plays an auxiliary role in T cell activation (Lazarovits, 1994; Stillwell, 2011), and is present on the surface of mature CD4<+> cells (Cotta, 2006; Lobac, 1985). CD7 has been extensively studied as a delivery target for cytotoxic molecules for leukemia and lymphoma treatment (Peipp, 2002; Bremmer, 2006; Franker, 1997; Vallera, 1996; Waurzyniak, 1997).
[0041] CD33 is a 67 kDa cell membrane protein that binds sialic acid and is a member of the sialic acid-binding Ig-related lectin (SIGLEC) family of proteins. CD33 is known to be expressed on myeloid cells. It has also been reported to be expressed on many malignant cells.
[0042] Whereas CD33, a common myeloid antigen, is expressed by the majority of AML cells (De Propris, MS et al., (2011) High CD33 expression levels in acute myeloid leukemia cells carrying the nucleophosmin (NPM1) mutation, haematological, 96 pp. 1548-1551; Ehninger, A. et al., (2014) Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia, Blood Cancer Journal, 4 pp. 1-10), CD7, a common marker for T cells and NK cells, is aberrantly expressed by a chemotherapy-resistant subpopulation (~22%) of AML cells, conferring a poor prognostic phenotype (Poeta, GD et al., (1995) CD7 Expression in Acute Myeloid Leukemia. Leuk. Lymphoma, 17, pp. 111-119; Rohrs, S. et al., (2010) CD7 in acute myeloid leukemia: correlation with loss of wild-type CEBPA, consequence of epigenetic regulation, Journal of Hematology & Oncology, 3 pp. 1-7; Rausei-Mills, V. et al., (2008) Aberrant Expression of CD7 in Myeloblasts Is Highly Associated With De Novo Acute Myeloid Leukemias With FLT3 / ITD Mutation, Am J Clin Pathol, 129 pp. 624-629; Shimamoto, T. et al. (1994) Clinical and Biological Characteristic of CD7+ Acute Myeloid Leukaemia, Cancer Genet Cytogenet 73 pp. 69-74; Reading, CLRaf, et al. (1993) Expression of unusual immunophenotype combinations in acute myelogenous leukemia, Blood 81: 3083-3090; Ossenkoppele, G. J., et al. (2011) Review of the relevance of aberrant antigen expression by flow cytometry in myeloid neoplasms British Journal of Haematology 153: 421-436; Lo Coco, F., et al. (1989) CD7 positive acute myeloid leukaemia: a subtype associated with cell immaturity, British Journal of Haematology 73: 480-485; Kita, K., et al. (1983) Clinical Importance of CD7 Expression in Acute Myelocytic Leukemia, Blood 81, 2399-2405; Eto, T., et al. (1992) Biological characteristics of CD7 positive acute myelogenous leukaemia, British Journal of Haematology 82: 508-511; Chang, H. (2004) Prognostic relevance of immunophenotyping in 379 patients with acute myeloid leukemia, Leukemia Research 28: 43-48).
[0043] The CD7+ subtype of AML is associated with leukocytosis, poor response to chemotherapy, and poor overall and disease-free survival (Kahl, C. et al. (2001) CD7+ and CD56+ Acute Myelogenous Leukemia is a Distinct Biologic and Clinical Disease Entity. Haematology and Blood Transfusion, 40 pp. 112-119). Clinically, CD7 AML patients are more prevalent among younger men, have a higher incidence of central nervous system involvement, and are more often associated with a less differentiated subtype of AML, further leading to a poorer prognosis (Tien, H. and Wang, C. (1998) CD7 Positive Hematopoietic Progenitors and Acute Myeloid Leukemia and other Minimally Differentiated Leukemia, Leukemia and Lymphoma, 3 pp. 93-98). The immature nature of CD7+ AML cells is further supported by the high expression of CD34 in this population. A study by Poeta et al. in 1995 showed that patients with CD7+ leukemia had a significantly lower CR than patients with leukemia of the CD7- phenotype (32% vs. 74%), indicating that this subtype exhibits a degree of relapse and / or refractory to standard treatment (Poeta, GD et al. (1995) CD7 Expression in Acute Myeloid Leukemia. Leuk. Lymphoma, 17, pp. 111-119).
[0044] CD7 is closely associated with and is considered to be a hallmark of the FLT3-ITD+ AML subgroup. This subtype is associated with worse clinical outcomes due to deregulation of the FLT3 tyrosine kinase receptor, which signals to downregulate the translation of apoptotic proteins, thereby inducing resistance to chemotherapy-induced cell death in AML cell populations (Rausei-Mills, V. et al., (2008) Aberrant Expression of CD7 in Myeloblasts Is Highly Associated With De Novo Acute Myeloid Leukemias With FLT3 / ITD Mutation, Am J Clin Pathol, 129 624-629). The FLT3 AML subgroup, which is a particularly poor prognostic subtype of AML, is a desirable disease group to target for novel drug developers, and many novel therapeutics, including kinase inhibitors and monospecific ADCs, specifically target this population.
[0045] Several mechanisms have been reported to explain the aberrant expression of CD7 in AML. These include disease-specific irregular gene expression in leukocytes (lineage infidelity), malignant transformation of multipotent progenitor cells capable of differentiating or proliferating into lymphoid or myeloid lineages, and arrest of maturation of rare progenitor cells that may transiently express markers of different cell lineages during normal cell differentiation (lineage promiscuity) (Tien, H. and Wang, C. (1998) CD7 Positive Hematopoietic Progenitors and Acute Myeloid Leukemia and other Minimally Differentiated Leukemia, Leukemia and Lymphoma, 3 pp. 93-98).
[0046] Transient CD7 expression has been reported on a subset of early progenitor cells that can generate cells of both myeloid and lymphoid origin, but is lost during transformation to mature myeloid or lymphoid lineages (Tien, H. and Wang, C. (1998) CD7 Positive Hematopoietic Progenitors and Acute Myeloid Leukemia and other Minimally Differentiated Leukemia, Leukemia and Lymphoma, 3 pp. 93-98). Similarly, one study showed that CD33 expression is expressed on pluripotent stem cells ( low / CD7 + / - ), some myeloid progenitor cells (CD33 high / CD7 + / - ), some T cell precursors (CD33 + / - / CD7 med The two antigens were identified as co-expressed at low levels in certain subsets of healthy hematopoietic cells, including CD7, CD8, CD9, CD10, CD11, CD12, CD13, CD24, CD15, CD25, CD16, CD26, CD17, CD27, CD28, CD19, CD29, CD29, CD30, CD40, CD18, CD29, CD19, CD29, CD31, CD41, CD19, CD29, CD14, CD29, CD15, CD29, CD16, CD29, CD17, CD29, CD29, CD18, CD29, CD19, CD29, CD29, CD31, CD19, CD29, CD16, CD29, CD19, CD29, CD29, CD19, CD29, CD29, CD31 ...
[0047] As used herein, the terms "treat", "treating" and "treatment" are intended to include interventions undertaken with the intent of preventing the onset or altering the pathology of a disorder or condition. Thus, "treatment" refers to both therapeutic treatment and prophylactic or preventative measures, the intent of which is to prevent or slow (alleviate) the disorder or condition of interest. Thus, the term "treating" encompasses treating and / or preventing the onset of a disorder or condition. As used herein, "treatment" refers to the prevention or treatment of a disease or disorder. Treatment may be prophylactic or therapeutic.
[0048] In such an embodiment, the antibodies, or antigen-binding fragments thereof, of the invention are administered to patients in remission of a hematological malignancy, thereby preventing or delaying recurrence of the underlying hematological malignancy.
[0049] As used herein, a "patient" is typically a human being treated for or diagnosed with a hematological malignancy, preferably a CD7+CD33+ hematological malignancy. In some embodiments, the antibody or antigen-binding fragment thereof is administered to a patient in remission of a CD7+CD33+ hematological malignancy, thereby preventing or delaying recurrence of the hematological malignancy. In some embodiments, the patient lacks detectable cells of the hematological malignancy. As used herein, "lack of detectable cells" is determined by standard diagnostic or prognostic methods. Patients in remission of AML typically show disappearance of abnormal clinical features, restoration of normal blood counts, and disappearance of normal hematopoiesis and leukemic clones in the bone marrow with less than 5% blasts, neutrophil counts greater than 1,000-1,500, and platelet counts greater than 100,000. See, e.g., The Merck Manual, Sec. 11, Ch. 138 (17th ed., 1997): Estey, 2001, Cancer 92(5): 1059-1073.
[0050] In some embodiments, a patient in remission from a CD7+CD33+ hematological malignancy has not undergone a bone marrow transplant. In other embodiments, a patient in remission from a CD7+CD33+ hematological malignancy has undergone a bone marrow transplant. The bone marrow transplant can be either an autologous or an allogeneic bone marrow transplant.
[0051] In embodiments, treating a CD7+CD33+ hematological malignancy (e.g., AML) and preventing or delaying recurrence of a CD7+CD33+ hematological malignancy (e.g., AML) comprises inducing AML cancer cell death and / or inhibiting AML cancer cell proliferation.
[0052] The antibody or antigen-binding fragment thereof may be part of a composition (e.g., a therapeutic composition) comprising a compound (i.e., the antibody or antigen-binding fragment thereof) and one or more other components. The composition may be a therapeutic composition comprising the antibody or antigen-binding fragment thereof and a pharma- ceutically acceptable excipient, adjuvant, diluent and / or carrier. Therapeutic compositions may routinely include pharma- ceutically acceptable concentrations of salts, buffers, preservatives, compatible carriers, supplemental immune enhancing agents such as adjuvants and cytokines, and, optionally, other therapeutic agents or compounds.
[0053] As used herein, "pharmaceutical acceptable" refers to a material that is biologically or otherwise desirable, i.e., a material that may be administered to an individual in conjunction with a selected compound without causing undesired biological effects or interacting in a deleterious manner with any of the other components of the pharmaceutical composition in which it is contained.
[0054] Excipients are natural or synthetic substances that are formulated with an active ingredient (e.g., a vaccine, a cell cycle inhibitor, a modulator of immune suppressive mechanisms, an immune checkpoint inhibitor (if appropriate)) to bulk the formulation or to impart a therapeutic effect to the active ingredient in the final dosage form, such as facilitating drug absorption or solubility. Excipients are also useful in the manufacturing process to aid in the handling of the active agent, such as promoting powder flowability and non-stickiness, as well as aiding in in vitro stability, such as preventing degradation during the expected shelf life. Pharmaceutically acceptable excipients are well known in the art. Thus, suitable excipients can be readily identified by one of ordinary skill in the art. By way of example, suitable pharma-ceutically acceptable excipients include water, saline, aqueous dextrose, glycerol, ethanol, and the like.
[0055] Adjuvants are pharmacological and / or immunological agents that modify the effect of other agents in the formulation. Pharmaceutically acceptable adjuvants are well known in the art. Thus, suitable adjuvants can be easily identified by those skilled in the art.
[0056] A diluent is an agent that is diluted. Pharmaceutically acceptable diluents are well known in the art. Thus, suitable diluents can be readily identified by those skilled in the art.
[0057] Carrier is non-toxic to recipients at the dosage and concentration used, and is compatible with other ingredients of the formulation.The term "carrier" refers to a natural or synthetic organic or inorganic ingredient that is mixed with active ingredient to facilitate application.Pharmaceutically acceptable carriers are well known in the art.Therefore, suitable carriers can be easily identified by those skilled in the art.
[0058] As used herein, the terms "effective amount" and "therapeutically effective amount" refer to an amount of an active therapeutic agent sufficient to produce a desired therapeutic response without excessive side effects such as toxicity, irritation, or allergic reaction. The specific "effective amount" will obviously vary depending on factors such as the particular condition being treated, the physical condition of the patient, the type of animal being treated, the duration of treatment, the nature of concurrent treatment (if any), the particular formulation and structure of the compound or its derivative employed. In this case, an amount is considered therapeutically effective if it produces one or more of the following, including, but not limited to, (a) inhibition of proliferation of cancer cells (e.g., AML cells), and (b) death of cancer cells (e.g., AML cells).
[0059] The dose of the antibody or antigen-binding fragment thereof and the therapeutic composition thereof administered to a patient may vary depending on the age and physique of the patient, the target disease, condition, administration route, etc. A preferred dose is typically calculated according to body weight or body surface area.
[0060] Methods of administration of the antibodies or antigen-binding fragments thereof and therapeutic compositions thereof include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The antibodies or antigen-binding fragments thereof and therapeutic compositions thereof may be administered by any convenient route, for example, by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.), and may be administered together with other biologically active agents. Administration may be systemic or local.
[0061] Preferably, the dual targeted therapy described herein will provide benefits for the treatment of CD7+CD33+ hematological malignancies in subjects in need thereof. For example, dual targeted therapy may have additive or synergistic effects on the treatment of AML in subjects in need thereof. Dual targeted therapy is defined as providing an "additive effect," "synergistic effect," or "synergistic treatment" if the effect is therapeutically superior to that achievable when one or the other of the components of the dual targeted therapy is administered at its conventional dose, as measured, for example, by the extent of response (e.g., apoptosis or cell viability), response rate, time to disease progression, or survival time. For example, the effect of dual targeted therapy is additive if the effect is therapeutically superior to that achievable by an antibody or antigen-binding fragment thereof that specifically binds to CD33 or CD7 alone. For example, the effect of a combined treatment may be synergistic if the effect of the combined treatment is superior to the combined effects of the individual treatments. Furthermore, the effect of the combination is beneficial (e.g., additive or synergistic) if a beneficial effect is obtained in a subject population that does not respond (or responds poorly) to a cytostatic agent that specifically binds CD33 alone or a cytostatic agent that specifically binds CD7 alone.Furthermore, the effect of a combination treatment is defined as providing a benefit (e.g., additive or synergistic effect) when the therapeutic effect, as measured, for example, by the degree of response, response rate, time to disease progression, or survival, is equal to or greater than that achievable when either one of the components of the combination treatment is administered in a conventional amount, when one of the components is administered at a conventional dose and the other component is administered at a reduced dose.
[0062] As used herein, "target cell killing" refers to, for example, inhibition of protein synthesis such that cell viability is reduced, or induction of apoptosis resulting in elimination or death of target cells. Assays for determining cell killing and apoptosis are well known in the art. Cytotoxicity assays evaluate the number of live and dead cells in a population after treatment with a pharmacological agent (e.g., LDH cytotoxicity assay, or live and dead cell assay). Apoptosis assays evaluate how cells are dying by measuring markers that are activated upon cell death (e.g., PS exposure assay, caspase activation assay, DNA fragmentation assay, GSH / GSSG measurement, LDH cytotoxicity assay, live and dead cell assay, or non-caspase protease activation assay).
[0063] As used herein, "inhibiting cell proliferation" (e.g., referring to a target cell) refers to a measurable decrease in the growth or proliferation of a target cell when contacted with an antibody or antigen-binding fragment thereof described in the present disclosure, compared to the proliferation of the same cell not contacted with the antibody or antigen-binding fragment thereof described in the present disclosure. For example, cell proliferation is inhibited by at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 99%, or 100%. Assays for determining cell viability or proliferation are well known in the art. Cell viability assays assess how healthy a cell is by measuring markers of cell activity (e.g., ATP and ADP determination assays, cell cycle assays, cell proliferation assays, cell viability assays, LHD cytotoxicity assays, or live and dead cell assays). Cell proliferation assays assess the growth rate of a cell population or detect daughter cells in a growing population (e.g., cell cycle assays, cell proliferation assays, cell viability assays, or senescence assays).
[0064] As used herein, "CD33-expressing cells" and "CD33+ cells" refer to cells that have CD33 as a surface antigen. As used herein, "CD7-expressing cells" and "CD7+ cells" refer to cells that have CD7 as a surface antigen. As used herein, "CD33- and CD7-expressing cells" and "CD33+CD7+ cells" refer to cells that have both CD33 and CD7 as surface antigens.
[0065] As used herein, "target cell" refers to a cell or cell type characterized by expression or overexpression of the target molecules CD7 and CD33. Any type of cell expressing CD7 and CD33 may be envisaged as a target cell for treatment with the antibody or antigen-binding fragment thereof of the invention. In certain embodiments, the cell is a tumor cell, e.g., a tumor cell from a hematological malignancy, such as an AML cell.
[0066] In certain embodiments, the antibodies or antigen-binding fragments thereof described herein can induce internalization of the antibodies or antigen-binding fragments thereof into CD33+ cells via the CD33 receptor and / or internalization of the antibodies or antigen-binding fragments thereof into CD7+ cells via the CD7 receptor. In certain embodiments, the antibodies or antigen-binding fragments thereof are antibodies or antigen-binding fragments thereof that specifically bind to both CD33 and CD7, and can induce internalization of an agent into CD7+CD33+ cells by binding to both CD7 and CD33 on the cell surface.
[0067] As used herein, "internalization via CD33 receptor" refers to uptake (i.e., entry) by CD33+ cells through binding of CD33 on the cell surface. In therapeutic applications, in vivo internalization is contemplated. As used herein, "internalization via CD7 receptor" refers to uptake (i.e., entry) by CD7+ cells through binding of CD7 on the cell surface. In therapeutic applications, in vivo internalization is contemplated.
[0068] In therapeutic applications, the number of internalized antibodies or antigen-binding fragments thereof will be sufficient or adequate to kill CD33+CD7+ cells, particularly CD7+CD33+ hematological cancer cells such as AML cells. Depending on the potency of the antibody or antigen-binding fragment thereof, in some cases, uptake of a single molecule into the cell is sufficient to kill the target cell to which the agent is bound.
[0069] In certain embodiments, the antibodies or antigen-binding fragments thereof of the present invention may be ADCs, small molecule drug conjugates (SMDCs), immunotoxins, peptide and non-peptide conjugates, imaging agents, therapeutic vaccines, nanoparticles.
[0070] The term "antibody" or "antibody" as used herein refers to a molecule or active fragment of a molecule that binds a known antigen, and in particular to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain a binding site that immunospecifically binds to an antigen (i.e., CD7 or CD33). Immunoglobulins according to the present invention may be of any class (IgG, IgM, IgD, IgE, IgA, and IgY) or subclass (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2) or subclass (isotype) of immunoglobulin molecule (e.g., IgG in IgG1, IgG2, IgG3, and IgG4, or IgA in IgA1 and IgA2).
[0071] Within the scope of the present invention, the term "antibody" or "antibody" includes human and humanized antibodies, as well as active fragments thereof. Examples of active fragments of molecules that bind to known antigens include Fab, F(ab'), F(ab') and F(ab'). 2 , scFv and Fv fragments are included, including the products of a Fab immunoglobulin expression library, and epitope-binding fragments of any of the above antibodies and fragments.
[0072] As used herein, the term "humanized antibody" or "humanized version of an antibody" refers to an antibody in which the framework or "complementarity determining regions" (CDRs) have been modified to include CDRs of an immunoglobulin with different specificity compared to the CDRs of the parent immunoglobulin. In some exemplary embodiments, the VH and VL CDRs are grafted into the framework regions of a human antibody to prepare a "humanized antibody." See, for example, Riechmann, L. et al., Nature 332 (1988) 323-327; and Neuberger, MS et al., Nature 314 (1985) 268-270. The heavy and light chain variable framework regions can be derived from the same or different human antibody sequences. The human antibody sequences can be sequences of naturally occurring human antibodies. Human heavy and light chain variable framework regions are listed, for example, in Lefranc, M.-P., Current Protocols in Immunology (2000)-Appendix 1P A.1P.1-A.1P.37, or can be accessed through IMGT, the international ImMunoGeneTics information System® (http: / / imgt.cines.fr), or http: / / vbase.mrc-cpe.cam.ac.uk, etc. Optionally, the framework regions can be modified by further mutations. Exemplary CDRs correspond to those representing sequences recognizing the antigens mentioned above for chimeric antibodies. In some embodiments, such humanized versions are chimerized with human constant regions. The term "humanized antibody" as used herein also includes such antibodies that have been modified in the constant region to generate the properties described in this disclosure, for example by "class switching", i.e. changes or mutations in the Fc part (e.g. IgG1 to IgG4 and / or IgG1 / IgG4 mutations), in particular with respect to C1q binding and / or FcR binding.
[0073] As used herein, the term "human antibody" is intended to include antibodies having variable and constant regions derived from human germline immunoglobulin sequences. Human antibodies are well known in the art (van Dijk, MA, and van de Winkel, JG, Curr. Opin. Chem. Biol. 5 (2001) pp. 368-374). Human antibodies can also be produced in transgenic animals (e.g., mice) capable of producing a full repertoire or selective production of human antibodies upon immunization in the absence of endogenous immunoglobulin production. Introduction of the human germline immunoglobulin gene array into such germline mutant mice results in the production of human antibodies upon antigen challenge (see, e.g., Jakobovits, A. et al., Proc. Natl. Acad. Sci. USA 90 (1993) pp. 2551-2555; Jakobovits, A. et al., Nature 362 (1993) pp. 255-258; Brueggemann, MD et al., Year Immunol. 7 (1993) pp. 33-40). Human antibodies can also be generated using phage display libraries (Hoogenboom, HR and Winter, G., J. Mol. Biol. 227 (1992) pp. 381-388; Marks, JD et al., J. Mol. Biol. 222 (1991) pp. 581-597). The techniques of Cole, A. et al. and Boerner, P. et al. are also available for the preparation of human monoclonal antibodies (Cole, A. et al., Monoclonal Antibodies and Cancer Therapy, Liss, AR (1985) p. 77; and Boerner, P. et al., J. Immunol. 147 (1991) p. 86-95). As already mentioned, the term "human antibody" as used herein also includes such antibodies which have been modified in the constant region to generate the properties described in the present disclosure, for example, by "class switching", i.e., alteration or mutation of the Fc portion (e.g., IgG1 to IgG4 and / or IgG1 / IgG4 mutation), for example, with respect to C1q binding and / or FcR binding.
[0074] As used herein, the term "antibody fragment" refers to a portion of a full-length antibody, and the term "antigen-binding fragment" refers to the variable domain thereof, or at least the antigen-binding site thereof, e.g., CDRs. Examples of antibody fragments include diabodies, single-chain antibody molecules, and multispecific antibodies formed from antibody fragments. scFv antibodies are described, for example, in Huston, JS, Methods in Enzymol. 203 (1991) pp. 46-88. Antibody fragments can be derived from the antibodies of the invention by a number of known techniques. For example, purified monoclonal antibodies can be cleaved with an enzyme such as pepsin and subjected to HPLC gel filtration. Appropriate fractions containing Fab fragments can then be collected and concentrated, e.g., by membrane filtration. For a more detailed description of general techniques for isolating active fragments of antibodies, see, e.g., Khaw, BA et al., J. Nucl. Med. 23:1011-1019 (1982); Rousseaux et al., Methods Enzymology, 121:663-69, Academic Press, 1986.
[0075] As used herein, the term "bispecific antibody" refers to an antibody that binds to two (or more) different antigens. A bispecific antibody usually comprises at least two different variable domains, each of which can specifically bind to a separate antigen. In certain embodiments, the bispecific antibody of the present invention is a human antibody. As used herein, the expression "bispecific antigen-binding molecule" refers to a protein, polypeptide, or molecular complex that comprises at least a first antigen-binding domain and a second antigen-binding domain. Each antigen-binding domain in a bispecific antigen-binding molecule comprises at least one CDR that specifically binds to a particular antigen, either alone or in combination with one or more additional CDRs. In the context of the present invention, the first antigen-binding domain specifically binds to a first antigen (e.g., CD7) and the second antigen-binding domain specifically binds to a second, different antigen (e.g., CD33). In certain embodiments, the bispecific molecule can simultaneously bind to human CD7 and human CD33.
[0076] In certain embodiments, bispecific antibodies may be referred to as "anti-CD7xCD33" or "anti-CD7 / anti-CD33," etc.
[0077] Any bispecific antibody format or technology may be used to generate the bispecific antigen-binding molecules of the present invention. Specific exemplary bispecific formats that can be used in the context of the present invention include, but are not limited to, for example, scFv-based or diabody bispecific formats, IgG-scFv fusions, dual variable domain (DVD)-lg, Quadroma, knob-into-hole, common light chain (e.g., common light chain with knob-into-hole, etc.), CrossMab, CrossFab, (SEED) body, leucine zipper, Duobody, lgG1 / lgG2, dual acting Fab (DAF)-lgG, Mab2 bispecific formats (see, e.g., Klein et al., 2012, imAbs 4:6, pp. 1-11, and references cited therein for a review of the above formats), and Fab-based bispecific formats. In certain embodiments, the bispecific antibody is a Fab-based anti-CD7 x CD33 bispecific.
[0078] As used herein, the terms "specific" and "specifically" are used interchangeably to indicate that there is no significant binding of a biomolecule other than CD7 or CD33 (or both CD7 and CD33 if the biomolecule is a bispecific molecule) to the antibody. In some embodiments, the level of binding to a biomolecule other than CD7 or CD33 is negligible (e.g., not determinable) by ELISA or affinity determination.
[0079] By "negligible binding" is meant binding that is at least about 85%, particularly at least about 90%, more particularly at least about 95%, even more particularly at least about 98%, especially at least about 99%, up to 100% lower than the binding to CD7 or CD33.
[0080] The binding affinity of an antibody to a peptide or epitope may be determined using standard binding assays such as surface plasmon resonance (BIAcore®, GE-Healthcare, Uppsala, Sweden). As used herein, the term "surface plasmon resonance" refers to an optical phenomenon that allows the analysis of real-time biospecific interactions by detecting changes in protein concentration within a biosensor matrix, for example using the BIAcore system (Pharmacia BiosensorAB, Uppsala, Sweden and Piscataway, NJ). For further details, see Jonsson, U. et al. (1993) Ann. Biol. Clin. 51:19-26; Jonsson, U. et al. (1991) Biotechniques 11:620-627; Johnsson, B. et al. (1995) J. Mol. Recognit. 8:125-131; and Johnnson, B. et al. (1991) Anal. Biochem. 198:268-277.
[0081] In one embodiment, the antibody or antigen-binding fragment thereof of the present invention can mediate antibody-dependent cellular cytotoxicity. Antibody-dependent cellular cytotoxicity (ADCC) is an immune effector cell-mediated mechanism that may contribute to the antitumor activity of monoclonal antibodies (Weiner GJ. Monoclonal antibody mechanisms of action in cancer. Immunol Res. 2007,39(1-3):271-8). The relevance of ADCC for antitumor effects has been demonstrated in preclinical models, e.g., mouse tumor models (e.g., Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med. 2000 April;6(4):443-6). Data from clinical trials support the relevance of ADCC for the clinical efficacy of antibody therapeutics (e.g., Weng WK, Levy R Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol. 2003 Nov. 1;21(21):3940-7, published online Sep. 15, 2003). Interaction of monoclonal antibodies with Fc receptors on immune cells contributes to ADCC. The Fc of antibodies can be modified to increase affinity for Fc receptors (e.g., Presta LG Engineering of therapeutic antibodies to minimize immunogenicity and optimize function. Adv Drug Deliv Rev. 2006 Aug. 7;58(5-6):640-56, published online May 23, 2006). This increased affinity for Fc receptors may increase ADCC activity and enhance antitumor efficacy in patients.
[0082] In an alternative embodiment, the antigen-binding fragment of the present invention is an immunoresponsive cell expressing a chimeric antigen T cell receptor protein (CAR), where the chimeric T cell receptor protein specifically binds to CD7 and CD33. In one embodiment, the immunoresponsive cell is bispecific and expresses a chimeric antigen T cell receptor protein (CAR), where the chimeric T cell receptor protein specifically binds to CD7 and the chimeric antigen T cell receptor protein (CAR), where the chimeric T cell receptor protein specifically binds to CD33. The immunoresponsive cell expressing a CAR may be selected from the group consisting of T cells, hematopoietic stem cells, natural killer cells, natural killer T cells, B cells, and monocyte lineage cells. In a particular embodiment, the immunoresponsive cell is a T cell.
[0083] In some embodiments, the immunoresponsive cells are autologous to the subject. In other embodiments, the immunoresponsive cells are not autologous to the subject. In certain embodiments, the immunoresponsive cells are T cells and are autologous to the subject being treated.
[0084] In some embodiments, the antibody or antigen-binding fragment thereof comprises a binding moiety (i.e., a CD33-binding moiety, a CD7-binding moiety, or a CD7- and CD33-binding moiety) and a cell-killing moiety. In certain embodiments, the cell-binding moiety is an antibody or an antigen-binding fragment thereof. In certain embodiments, the cell-binding moiety is an antibody or an antigen-binding fragment thereof.
[0085] In some embodiments, the antibody or antigen-binding fragment thereof further comprises (or is incorporated into or associated with) a cytotoxic or cytostatic agent, i.e., a compound that kills or inhibits tumor cells. Such agents may exert their cytotoxic and cytostatic effects by mechanisms including tubulin binding, DNA binding, proteasome and / or topoisomerase inhibition.
[0086] The cytotoxic or cytostatic agent can be, for example, a peptide toxin, a small molecule toxin or a radioisotope.
[0087] In one embodiment, the cytotoxic or cytostatic agent may be a tubulin inhibitor or a DNA-interactive agent. Tubulin inhibitors modulate tubulin polymerization. DNA-interactive agents target cellular DNA.
[0088] In one embodiment, the cytotoxic or cytostatic agent is a tubulin inhibitor. In one embodiment, the tubulin inhibitor is selected from the group consisting of (a) an auristatin, and (b) a maytansine derivative. In one embodiment, the cytotoxic or cytostatic agent is an auristatin. Auristatins include synthetic derivatives of the naturally occurring compound dolastatin-10. Auristatins are a family of antitumor / cytostatic pseudopeptides. Dolastatins are structurally unique due to the incorporation of four rare amino acids (Dolavaine, Dolaisoleuine, Dolaproine, and Dolaphenine) identified in natural biosynthetic products. Additionally, this class of natural products possesses multiple asymmetric centers defined by total synthesis work by Pettit et al. (US Pat. No. 4,978,744). Structure-activity relationships suggest that dolaisoleoin and dolaproin residues are necessary for antitumor activity (US 5,635,483 and US 5,780,588). In one embodiment, the auristatin is selected from the group consisting of auristatin E (AE), monomethylauristatin E (MMAE), auristatin F (MMAF), vcMMAE, vcMMAF, mcMMAE, and mcMMAF. In one embodiment, the cytotoxic or cytostatic agent is maytansine or a structural analogue of maytansine. In one embodiment, the cytotoxic or cytostatic agent is maytansine. Maytansines include structurally complex antimitotic polypeptides. Maytansines are potent inhibitors of microtubule assembly leading to apoptosis of tumor cells. In one embodiment, the maytansine is selected from the group consisting of mertansine (DM1) and structural analogues of maytansine such as DM3 or DM4. Preferably, the drug is mertansine (DM1).
[0089] In one embodiment, the cytotoxic or cytostatic agent is a DNA interacting agent. In one embodiment, the DNA interacting agent is selected from the group consisting of (a) a calicheamicin, (b) a duocarmycin, and (c) a pyrrolobenzodiazepine (PBD). In one embodiment, the cytotoxic or cytostatic agent is a calicheamicin. Calicheamicin is a potent cytotoxic agent that causes double-stranded DNA breaks, resulting in cell death. Calicheamicin is a naturally occurring enediyne antibiotic (AL Smith et al., J. Med. Chem., 1996, 39,11, pp. 2103-2117). Calicheamicin was discovered in the soil microorganism Micromonospora echinospora. In one embodiment, the calicheamicin is calicheamicin γ1. In one embodiment, the drug is a duocarmycin. Duocarmycins are potent antitumor antibiotics that exert their biological effects by sequence-selectively binding to the minor groove of the DNA duplex and alkylating the N3 of adenine (D. Boger, Pure & Appl. Chem., 1994, 66, 4, pp. 837-844). In one embodiment, the duocarmycin is selected from the group consisting of duocarmycin A, duocarmycin B1, duocarmycin B2, duocarmycin C1, duocarmycin C2, duocarmycin D, duocarmycin SA, cyclopropylbenzoindole (CBI) duocarmycin, centanamycin, rachelmycin (CC-1065), adozelesin, bizelesin, and carzelesin. In one embodiment, the cytotoxic or cytostatic agent is a pyrrolobenzodiazepine. Pyrrolobenzodiazepines (PBDs) are a class of naturally occurring antitumor antibiotics. Pyrrolobenzodiazepines are found in the genus Streptomyces. PBD exerts its antitumor activity by binding specifically to the minor groove of DNA via a purine-guanine-purine unit. PBD inserts into the N2 of guanine via an amine bond, and due to its shape, DNA helix disruption is minimal. Formation of DNA-PBD adducts is thought to inhibit nucleic acid synthesis and induce DNA helix break-dependent single- and double-strand breaks.As a synthetic derivative, two PBD units are linked via a flexible polymethylene tether, allowing the PBD dimer to crosslink opposing DNA strands and produce a highly lethal lesion. In one embodiment, the cytotoxic or cytostatic agent is a synthetic derivative of two pyrrolobenzodiazepine units linked via a flexible polymethylene tether. In one embodiment, the pyrrolobenzodiazepine is selected from the group consisting of Anthramycin (and its dimer), Mazethramycin (and its dimer), Tomaymycin (and its dimer), Prothracarcin (and its dimer), Chicamycin (and its dimer), Neothramycin A (and its dimer), Neothramycin B (and its dimer), DC-81 (and its dimer), Sibiromycin (and its dimer), Porothramycin A (and its dimer), Porothramycin B (and its dimer), Sivanomycin (and its dimer), Abbeymycin (and its dimer), SG2000, and SG2285.
[0090] In one embodiment, the cytotoxic or cytostatic agent is a drug that targets DNA interstrand crosslinks through alkylation. Drugs that target DNA interstrand crosslinks through alkylation are selected from DNA-targeted mustards, guanine-specific alkylating agents, and adenine-specific alkylating agents. In one embodiment, the cytotoxic or cytostatic agent is a DNA-targeted mustard. For example, the DNA-targeted mustard may be selected from the group consisting of oligopyrroles, oligoimidazoles, bis-(benzimidazole) carriers, polybenzamide carriers, and 9-anilinoacridine-4-carboxamide carriers.
[0091] In one embodiment, the cytotoxic or cytostatic agent is selected from the group consisting of netropsin, distamycin, lexitropsin, talimustine, dibromotalimustine, PNU157977, and MEN10710.
[0092] In one embodiment, the cytotoxic or cytostatic agent is a bis-(benzimidazole) carrier. Preferably, the drug is Hoechst 33258.
[0093] Guanine-specific alkylating agents are highly position-specific alkylating agents that react at specific nucleoside positions. In one embodiment, the cytotoxic or cytostatic agent is a guanine-specific alkylating agent selected from the group consisting of G-N2 alkylating agents, A-N3 alkylating agents, mitomycin, carmethizole analogs, and ecteinascidin analogs. In one embodiment, the mitomycin is selected from mitomycin A, mitomycin C, porfiromycin, and KW-2149. In one embodiment, the carmethizole analog is selected from bis-(hydroxymethyl)pyrrolizidine and NSC602668. In one embodiment, the ecteinascidin analog is ecteinascidin 743.
[0094] Adenine-specific alkylating agents are site- and sequence-specific minor groove alkylating agents that react with the N3 of adenine in polypyrimidine sequences.
[0095] Cyclopropindolone and duocamicin may be defined as adenine-specific alkylating agents. In one embodiment, the cytotoxic or cytostatic agent is a cyclopropindolone analog. Preferably, the drug is selected from adozelesin and carzelesin.
[0096] In one embodiment, the cytotoxic or cytostatic agent is a benz[e]indolone. Preferably, the cytotoxic or cytostatic agent is selected from CBI-TMI and iso-CBI.
[0097] In one embodiment, the cytotoxic or cytostatic agent is bizelesin.
[0098] In one embodiment, the cytotoxic or cytostatic agent is a marine antitumor drug. Marine antitumor drugs are a developing field in the field of antitumor drug development (I. Bhatnagar et al., Mar. Drugs 2010, 8, 2702-2720, and TL Simmons et al., Mol. Cancer Ther. 2005, 4(2), 333-342). Marine organisms such as sponges, sponge-microbe symbionts, gorgonians, actinomycetes, and soft corals have been widely explored as potential anticancer drugs.
[0099] In one embodiment, the cytotoxic or cytostatic agent is selected from cytarabine, Ara-C, trabectedin (ET-743), and eribulin mesylate. In one embodiment, eribulin mesylate is selected from the group consisting of (E7389), sobridotin (TZT 1027), squalamine lactate, cemadotin plinabulin (NPI-2358), plitidepsin, erysidepsin, Zalypsis, tacidotin, synthadotin, (ILX-651), discodermolide, HT1286, LAF389, kahalalide F, KRN7000, bryostatin 1, hemiasterin (E7974), marizomib, salinosporamide A (NPI-0052), LY355703, CRYPTO 52, Depsipeptide (NSC630176), Ecteinascidin 743, Sinsadotin, Kahalalide F, Squalamine, Dehydrodidemnin B, Didemnin B, Cemadotin, Sobridotin, E7389, NVP-LAQ824, Discodermolide, HTI-286, LAF-389, KRN-7000 (Agelasphin derivative), Curacin A, DMMC, Salinosporamide A, Laulimalide, Bitilebamide (V itilevuamide, diazonamide, erytherobin, sarcodictyin, peloruside A, salicylihalimide A and B, thiocoraline, ascididemin, variolin, lamellarin D, dictyodendrin, ES-285 (spislosin), and halichondrin B.
[0100] The following cytotoxic or cytostatic agents are also encompassed by the present invention: amatoxin (α-amanitin) bicyclic octapeptide produced by basidiomycetes of the genus Amanita, such as the Green Deathcap mushroom, tubulysin, cytolysin, dolabellanin, epothilones A, B, C, D, E, F. Epothilones - constitute a group of non-taxane tubulin polymerizing agents, obtained by natural fermentation of the myxobacterium Sorangium cellulosum. These moieties have potent cytotoxic activity, which is associated with the stabilization of microtubules, leading to mitotic arrest at the G2 / M transition. Epothilones are potently cytotoxic in various cancer cell lines, often with greater activity than paclitaxel (X.: Pivot et al., European Oncology, 2008;4(2), pp. 42-45). In one embodiment, the drug is an amatoxin. In one embodiment, the drug is a tubulysin. In one embodiment, the drug is a cytolysin. In one embodiment, the drug is a dolabellanine. In one embodiment, the drug is an epothilone.
[0101] The following cytotoxic or cytostatic agents are also encompassed by the present invention: In one embodiment, the drug is doxorubicin, epirubicin, esorubicin, detorubicin, morpholino-doxorubicin, methotrexate, methopterin, bleomycin, dichloromethotrexate, 5-fluorouracil, cytosine-β-D-arabinofuranoside, taxol, anguidin, melphalan, vinblastine, phomopsin A, ribosome-inactivating protein (RIP), daunorubicin, vinca alkaloids, idarubicin, melphalan, cisplatin, ricin , saporin, anthracyclines, indolino-benzodiazepines, 6-mercaptopurine, actinomycin, leurosine, leurosideine, carminomycin, aminopterin, tallysomycin, podophyllotoxin, etoposide, hairpin polyamides, etoposide phosphate, vinblastine, vincristine, vindesine, taxotere retinoic acid, N8-acetylspermidine, camptothecin, esperamicin, and enediyne.
[0102] In one embodiment, the cell-killing moiety is a peptide toxin, e.g., an auristatin such as MMAE. In one embodiment, the antibody or antigen-binding fragment thereof comprises a binding moiety and a cell-killing moiety, wherein the binding moiety is an anti-CD7 anti-CD33 bispecific antibody or binding portion thereof, and the cell-killing moiety is a peptide toxin, e.g., an auristatin such as MMAE.
[0103] In certain embodiments, the antibody or antigen-binding fragment thereof comprises a binding moiety conjugated to a cell-killing moiety. Such conjugates can be prepared by in vitro methods known to those skilled in the art. Techniques for conjugating cytotoxic or cytostatic agents to proteins, particularly antibodies, are well known. (See, for example, Alley et al., Current Opinion in Chemical Biology 2010 14: 1-9; Senter, Cancer J., 2008, 14(3): 154-169).
[0104] In certain embodiments, a linking group is used to conjugate the binding moiety and the cell-killing moiety.
[0105] The linker is cleavable under intracellular conditions, and cleavage of the linker releases the cell-killing moiety from the binding moiety in the intracellular environment. The cleavable linker can be, for example, a peptidyl linker that is cleaved by an intracellular peptidase or protease enzyme, including a lysosomal protease or an endosomal protease. Cleavage agents include cathepsin B and D, plasmin, and the like (see, for example, Dubowchik and Walker, Pharm. Therapeutics 83:67-123, 1999). Most typical are peptidyl linkers that are cleavable by enzymes present in NTB-A-expressing cells. For example, a peptidyl linker that is cleavable by cathepsin B, a thiol-dependent protease that is highly expressed in cancer tissues, can be used (e.g., a linker containing a Phe-Leu or Val-Cit peptide).
[0106] The cleavable linker is pH sensitive, i.e., sensitive to hydrolysis at a certain pH value. Typically, the pH sensitive linker is hydrolyzable under acidic conditions. For example, an acid-labile linker (e.g., hydrazone, semicarbazone, thiosemicarbazone, cis-aconitic amide, orthoester, acetal, ketal, etc.) that is hydrolyzable in the lysosome can be used.
[0107] Other linkers are cleavable under reducing conditions (e.g., disulfide linkers). The cleavable linker can also be a malonic acid linker (Johnson et al., Anticancer Res. 15:1387-93, 1995), a maleimidobenzoyl linker (Lau et al., Bioorg-Med-Chem. 3:1299-1304, 1995), or a 3'-N-amide analog (Lau et al., Bioorg-Med-Chem. 3:1305-12, 1995).
[0108] In some embodiments, the linker may be a protease-cleavable linker, such as valine-citrulline, which may be cleaved by cathepsin B in the lysosome.
[0109] The linker can also be a non-cleavable linker, such as a maleimide-alkylene or maleimide-aryl linker, which is directly attached to the therapeutic agent and released by proteolysis of the linked moiety.
[0110] Throughout the description and claims of this specification, the words "comprise" and "contain" and variations thereof mean "including, but not limited to," and are not intended to (and do not) exclude other moieties, additives, ingredients, integers, or steps. Throughout the description and claims of this specification, the singular includes the plural, unless otherwise indicated. In particular, where the indefinite article is used, the specification is to be understood as plural as well as singular, unless otherwise indicated.
[0111] It is to be understood that any feature, integer, property, compound, chemical moiety or group described in connection with a particular aspect, embodiment or example of the invention is applicable to any other aspect, embodiment or example described herein, except where inconsistent. All features disclosed in this specification (including the accompanying claims, abstract and drawings), and / or all steps of any method or process so disclosed, may be combined in any combination, except combinations in which at least some of such features and / or steps are mutually exclusive. The invention is not limited to the details of the foregoing embodiments. The invention extends to any novel one, or any novel combination, of the features disclosed in this specification (including the accompanying claims, abstract and drawings), or any novel one, or any novel combination of the steps of any method or process so disclosed.
[0112] Embodiments of the invention will now be described, by way of example only, with reference to the following figures: [Brief description of the drawings]
[0113] [Figure 1] Figure 1 is a bar graph showing binding of reduced affinity bi-Fabs at 10 nM to CD33+ / CD7+ cell lines, normal PBMC monocytes, and T cells isolated from healthy human donors. 50,000 cells of HNT-34 (CD33+ / CD7+), Kasumi-3 (CD33+ / CD7+), Jurkat (CD33- / CD7+), SHI-1 (CD33+ / CD7-), healthy PBMC monocytes (CD33+ / CD7-), and healthy T cells (CD33- / CD7+) were tested for CD33+ / CD7+ bi-Fab antibodies. Cells were resuspended in 100 μl of 10 nM bi-Fab for 1 hour on ice. After incubation, cells were pelleted and incubated with 50 μl of mouse anti-human IgG Fab secondary antibody, PE, diluted 1 in 17 in ice-cold PBS / 0.1% BSA for an additional hour on ice. Cells were washed, resuspended in PBS and analyzed on a FACS Calibur and data were plotted in Excel. [Diagram 2] Figure 1 is a bar graph showing binding of each reduced affinity bi-Fab at 10 nM to CD33+ / CD7+ cell lines, normal PBMC monocytes, and T cells isolated from healthy human donors. 50,000 cells of HNT-34 (CD33+ / CD7+), Kasumi-3 (CD33+ / CD7+), Jurkat (CD33- / CD7+), SHI-1 (CD33+ / CD7-), healthy PBMC monocytes (CD33+ / CD7-), and healthy T cells (CD33- / CD7+) were tested for CD33+ / CD7+ bi-Fab antibodies. Cells were resuspended in 100 μl of 10 nM bi-Fab for 1 hour on ice. After incubation, cells were pelleted and incubated with 50 μl of mouse anti-human IgG Fab secondary antibody, PE, diluted 1 in 17 in ice-cold PBS / 0.1% BSA for an additional hour on ice. Cells were washed, resuspended in PBS and analyzed on a FACS Calibur and data were plotted in Excel. [Diagram 3]FIG. 1 is a graph illustrating a cell killing assay performed with a 10-point dose response of directly conjugated BVX130-MMAF to 2×10 Kasumi-3 (CD33+ / CD7+) cells per well. Plates were incubated at 37° C., 5% CO2 for 96 hours. After incubation, 5 μl of Alamar Blue reagent was added per well and plates were read after further incubation at 37° C., 5% CO2 for 4 and 6 hours. Data for each read was plotted in GraphPad PRISM and IC50 values were recorded. IC50 was calculated using the 4 hour read data for cell line Kasumi-3. IC50 was 0.1235 nM. [Figure 4] FIG. 1 is a graph illustrating a cell killing assay performed with a 10-point dose response of directly conjugated BVX130-MMAF to 2×104 HNT-34 (CD33+ / CD7+) cells per well. Plates were incubated at 37° C., 5% CO2 for 96 hours. After incubation, 5 μl of Alamar Blue reagent was added per well and plates were read after further incubation at 37° C., 5% CO2 for 4 and 6 hours. Data for each read was plotted in GraphPad PRISM and IC50 values were recorded. IC50 was calculated using the 4 hour read data for cell line HNT-34. IC50 was 0.1204 nM. [Diagram 5] FIG. 1 is a graph illustrating a cell killing assay performed with a 10-point dose response of directly conjugated BVX100-MMAF to 2×10 Kasumi-3 (CD33+ / CD7+) cells per well. Plates were incubated at 37° C., 5% CO2 for 96 hours. After incubation, 5 μl of Alamar Blue reagent was added per well and plates were read after further incubation at 37° C., 5% CO2 for 4 and 6 hours. Data for each read was plotted in GraphPad PRISM and IC50 values were recorded. IC50 was calculated using the 4 hour read data for cell line Kasumi-3. IC50 was 0.0651 nM. [Figure 6] FIG. 1 is a graph illustrating a cell killing assay performed with a 10-point dose response of directly conjugated BVX100-MMAF to 2×104 HNT-34 (CD33+ / CD7+) cells per well. Plates were incubated at 37° C., 5% CO2 for 96 hours. After incubation, 5 μl of Alamar Blue reagent was added per well and plates were read after further incubation at 37° C., 5% CO2 for 4 and 6 hours. Data for each read was plotted in GraphPad PRISM and IC50 values were recorded. IC50 was calculated using the 4 hour read data for cell line HNT-34. IC50 was 0.2437 nM. [Figure 7] FIG. 1 is a graph showing dose response curves for a cell killing assay performed with 9 doses of directly conjugated BVX130-MMAE or BVX100-MMAE on 2×104 Jurkat cells (CD33− / CD7+) per well up to a final concentration of 30 nM. Plates were incubated at 37° C., 5% CO2 for 96 hours. After incubation, 10 μl of CellTiter 96 AQueous One Solution was pipetted into each well and plates were incubated for an additional 3 hours at 37° C., 5% CO2. Absorbance was read at 492 nm and 690 nm. OD690 nm was subtracted from OD492 nm and data was plotted using GraphPad PRISM software. Error bars represent standard deviation of quadruplicate replicates. [Figure 8]FIG. 1 is a graph showing dose response curves for a cell killing assay performed with a 10-point dose response of directly conjugated BVX130-MMAF or BVX100-MMAF on 2×104 Jurkat cells (CD33− / CD7+) per well up to a final concentration of 30 nM. Plates were incubated at 37° C., 5% CO2 for 96 hours. After incubation, 5 μl of Alamar Blue reagent was added per well and plates were read after further incubation at 37° C., 5% CO2 for 4 and 6 hours. Data for each read was plotted in GraphPad PRISM and IC50 values were recorded. IC50 was calculated using the 4 hour read data for the Jurkat cell line. Error bars represent standard deviation of quadruplicates. [Figure 9] FIG. 1 is a graph showing dose response curves for a cell killing assay performed with a 10-point dose response of directly conjugated BVX130-MMAF or BVX100-MMAF on 2×104 LOUCY cells (CD33− / CD7+) per well up to a final concentration of 30 nM. Plates were incubated at 37° C., 5% CO2 for 96 hours. After incubation, 5 μl of Alamar Blue reagent was added per well and plates were read after further incubation at 37° C., 5% CO2 for 4 and 6 hours. Data for each read was plotted in GraphPad PRISM and IC50 values were recorded. IC50 was calculated using the 4 hour read data for the LOUCY cell line. Error bars represent standard deviation of quadruplicates. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0114] Example 1 Assessment of binding of different CD33+ / CD7+ bi-Fabs in cell lines and primary cells The binding of different CD33+ / CD7+ conjugated bispecific antibodies was evaluated on various cell lines and primary cells from healthy human donors. Each conjugated bispecific antibody displayed a different pair of binding arms targeting either CD33 or CD7 (Table 1). The binding arms of each bispecific antibody show different affinities for CD33 or CD7.
[0115] [Table 1]
[0116] [Table 2]
[0117] reagent Mouse anti-human IgG Fab secondary antibody, PE ThermoFisher #MA110377 Jurkat cells DSMZ282 Kasumi-3 cells DSMZ714 HNT-34 cells DSMZ600 SHI-1 cells DSMZ645 Healthy PBMC donor 1 Cambridge Bioscience ID PR18E125592 PBS / A (Catalog number 50086470) VWR BSA (Bovine Serum Albumin Fraction V 100ml 7.5% Catalog No. 15260037) ThermoFisher BVX1001 BVX1101 BVX1201 BVX1301 BVX1401 BVX1501 BVX1601 BVX1011 BVX1611 BVX1021 BVX1521 BVX1621 BVX1631
[0118] method 1 ml of each bi-Fab preparation was prepared at 10 nM in PBS / 0.1% BSA. Cells were harvested and counted to provide sufficient cell numbers to test each bi-Fab with each bi-Fab dilution, plus samples labeled with secondary antibody only, using 50,000 cells per test. For PBMC samples, 100,000 cells were used per test. Cells were pelleted at 1000 rpm for 5 minutes at 4°C and resuspended in ice-cold PBS. A 100 μl aliquot of each cell sample was pipetted into each well of a V-bottom 96-well plate on ice. Cells were pelleted at 1000 rpm for 5 minutes at 4°C and the supernatant was aspirated. Cells were resuspended in 100 μl of 10 nM bi-Fab. Plates were incubated on ice for 1 hour. 75 μl of ice-cold PBS was added to each well and cells were pelleted at 1000 rpm for 5 minutes at 4°C. The supernatant was aspirated and the cells were resuspended in 50 μl of mouse anti-human IgG Fab secondary antibody, PE, diluted 1 in 17 in ice-cold PBS / 0.1% BSA. The plate was incubated on ice for 1 hour. 100 μl of ice-cold PBS was added to each well and the cells were pelleted at 1000 rpm for 5 minutes at 4°C. The cells were resuspended in 300 μl of ice-cold PBS, transferred to FACS tubes and analyzed fluorescently using a FACS Calibur to detect PE staining with FL2.
[0119] Monocyte populations in PBMC samples were identified from side scatter / forward scatter dot plots and data were plotted in Excel.
[0120] result The binding of each bispecific antibody (1 nM and 10 nM) to each cell line was assessed in parallel with the binding to monocytes and T cells isolated from healthy human donors (Figures 1 and 2). As can be seen from the data, the specific CD7 and CD33 constructs used within each bispecific construct affect binding to dual (CD33+ / CD7+) versus single (CD33+ / CD7- or CD33- / CD7+) antigen positive cell lines and primary cells isolated from healthy human donors.
[0121] [Table 3-1]
[0122] [Table 3-2]
[0123] [Table 3-3]
[0124] [Table 3-4]
[0125] Figures 1 and 2 show that reducing the binding affinity of the CD7 binding arm of a bispecific antibody that also contains a wild-type CD33 binding arm does not affect the binding affinity to CD7+ / CD33+ cell lines. Surprisingly, binding of the bispecific construct to CD33- / CD7+ cells was affected by the affinity of both the CD7 and CD33 arms used within the construct. Table 2 above shows the results for the bispecific antibodies tested, and the data is summarized in Table 3, which includes the fold reduction in binding affinity of each binding arm of each bispecific antibody.
[0126] [Table 4]
[0127] Example 2 Evaluation of cytotoxicity in CD7+CD33+ immortalized cell lines The cytotoxicity (cell killing) efficiency of CD33+ / CD7+ bispecific antibody drug conjugates was evaluated in multiple CD33+ / CD7+ cell lines.
[0128] Test drug BVX100-MMAF - CD33 monobinder x CD7 monobinder bi-Fab conjugated to mcMMAF (cytotoxic payload) BVX130-MMAF - a CD33 monobinder × CD7 monobinder bi-Fab conjugated to a partially optimized mcMMAF (cytotoxic payload) CD7 monobinder (i.e., different CD7 protein sequence compared to BVX100-MMAF) CD33×CD33-MMAF - bi-Fab of CD33 monobinder×CD33 monobinder conjugated to mcMMAF (cytotoxic payload) Gemtuzumab-MMAF - Gemtuzumab is the commercially available CD33 monospecific IgG antibody component of Pfizer's ADC Mylotarg™, conjugated to mcMMAF (a cytotoxic payload). All ADC conjugates used the same payload, conjugation technology, and same drug:antibody ratio.
[0129] reagent · Kasumi-3 cells DSMZ714 · HNT-34 cells DSMZ600 BVX130-MMAF (P01-32, 10.5μM) In-house - Head of Chemistry BVX130-MMAE (193-27-3, 49μM) In-house - Head of Chemistry BVX100-MMAF (193-15, 13μM) In-house - Head of Chemistry BVX100-MMAE (193-28, 34μM) In-house - Head of Chemistry BSA (Bovine serum albumin fraction V 100ml 7.5% Catalog number 15260037) ThermoFisher PBS / A (Cat. No. 50086470) VWR Corning 384-well clear flat-bottom polystyrene TC-treated microplates, SLS alamarBlue™ Cell Viability Reagent (DAL1025) ThermoFisher RPMI-1640 medium 21875034 Gibco, LifeTechnologies GlutaMAX™ Nutritional Supplement 35050061 Gibco, a LifeTechnologies company Fetal bovine serum, heat inactivated 10500064 Gibco, LifeTechnologies Penicillin-streptomycin (10,000U / mL) 15140122 Gibco, LifeTechnologies
[0130] method Kasumi-3 and HNT-34 cell lines were harvested and counted, and the amount needed to seed 2000 cells per well across 100 wells in 40 μl of medium per well was calculated for a 384-well plate. A 10-point dose response of BVX130-MMAE, BVX130-MMAF, BVX100-MMAE and BVX100-MMAF was prepared in assay medium (RPMI, 10% FBS, 1% Glutamax, 1% Pen / Strep) at 5x the final concentration, with a maximum final concentration of 30 nM. 10 μl of each dose was pipetted into triplicate wells of a 384-well plate, with a separate plate for each cell line tested. 500,000 cells from each cell line were pipetted into 5 ml of assay medium and the cells were pelleted. Each cell pellet was resuspended in 10 ml of assay medium and 40 μl was pipetted into the indicated wells. 50 μl of assay medium was pipetted into blank control wells and 50 μl of PBS was pipetted into all spare wells and the plates were incubated at 37° C., 5% CO2 for 4 or 7 days. After 4 days of incubation, 5 μl of Alamar Blue reagent was added per well and the plates were read after further incubation at 37° C., 5% CO2 for 4 and 6 hours. Data for each reading were plotted in GraphPad PRISM and IC50 values were recorded. The 4 hour reading data for cell lines Kasumi-3 and HNT-34 were used in the IC50 summary table.
[0131] result Examples of dose response curves for each of these assays are shown in Figures 3 to 6. Briefly, each CD33+ / CD7+ bispecific antibody drug conjugate exhibited robust cytotoxicity in different CD33+ / CD7+ cell lines. Table 4 below summarizes the average cytotoxicity IC50 of each bispecific antibody in each cell type across multiple experiments.
[0132] [Table 5]
[0133] FIG. 3 is a graph showing a dose-response curve of cytotoxicity resulting from exposure of Kasumi-3 cells to increasing concentrations of BVX130-MMAF. Kasumi-3 cells are CD33+ / CD7+, and BVX130-MMAF is a reduced affinity CD33+ / CD7+ bispecific antibody conjugated with a cytotoxic payload. An example IC50 of BVX130-MMAF in Kasumi-3 cells is 0.1235 nM, with an average IC50 of 13 experiments of 0.16 nM. The average IC50 of 12 experiments of the same bispecific antibody conjugate in HNT-34 cells (CD33+ / CD7+) is 0.37 nM. FIG. 4 is an example of a dose-response curve resulting from exposure of HNT-34 cells to increasing concentrations of BVX130-MMAF.
[0134] BVX130-MMAF contains a partially optimized CD7 sequence compared to BVX100-MMAF. Figures 5 and 6 are examples of dose-response curves using BVX100-MMAF as a bispecific antibody drug conjugate. As with BVX130-MMAF, the cell types tested were Kasumi-3 and HNT-34, both of which are CD33+ / CD7+. The average IC50 of BVX100-MMAF in Kasumi-3 cells is 0.11 nM over six experiments. The average IC50 of BVX100-MMAF in HNT-34 cells is 0.41 nM over four experiments.
[0135] MMAF-conjugated bispecific antibodies generally show higher IC50 in each cell type, as shown in Table 4. For example, the average IC50 of BVX130-MMAF in Kasumi-3 cells is 0.16 nM, whereas the IC50 of BVX130-MMAE in the same cell type is 0.45 nM. The same is true when considering BVX100-MMAF vs. BVX100-MMAE in the same cell line.
[0136] overview The above results show that each of the bispecific CD33+ / CD7+ antibodies conjugated to a cytotoxic payload induces effective cell death in two CD33+ / CD7+ cell lines. The next step was to determine whether exposure to these bispecific antibody drug conjugates induces off-target cytotoxicity in cells expressing only CD33 or CD7 as single targets, which are representative of single antigen positive healthy cell populations in blood. This was assessed by determining the fold selectivity in cell death using the bispecific antibody panel conjugated to a cytotoxic payload in CD33+ / CD7+ cell lines versus CD33+ / CD7- and CD33- / CD7+ cell lines.
[0137] Example 3 Evaluation of selectivity of CD33+ / CD7+ versus CD33+ / CD7- and CD33- / CD7+ cells To investigate whether certain bispecific antibodies conjugated to a cytotoxic payload preferentially target CD33+ / CD7+ cells over CD33+ / CD7- and CD33- / CD7+ cells, a panel of dual- and single-antigen-positive immortalized cell lines was exposed to various conjugated CD7+ / CD33+ bispecific antibodies and cytotoxicity was measured.
[0138] Cytotoxic activity of Bi-Fab-MMAE conjugates in CD33 and CD7 double- and single-positive cell lines reagent · Kasumi-3 cells DSMZ714 · HNT-34 cells DSMZ600 · SHI-1 cells DSMZ645 · MV4.11 cells DSMZ102 · Jurkat cells DSMZ282 Internal - Chemistry Department Manager BVX100-MMAE BVX110-MMAE BVX120-MMAE BVX130-MMAE BVX140-MMAE BVX150-MMAE BVX160-MMAE BSA (Bovine serum albumin fraction V 100ml 7.5% Catalog number 15260037) ThermoFisher PBS / A (Cat. No. 50086470) VWR Corning 384-well clear flat-bottom polystyrene TC-treated microplates, SLS alamarBlue™ Cell Viability Reagent (DAL1025) ThermoFisher RPMI-1640 medium 21875034 Gibco, LifeTechnologies GlutaMAX™ Nutritional Supplement 35050061 Gibco, a LifeTechnologies company Fetal bovine serum, heat inactivated 10500064 Gibco, LifeTechnologies Penicillin-streptomycin (10,000U / mL) 15140122 Gibco, LifeTechnologies
[0139] method Cells were harvested, counted, and plated at 2 x 10 cells per 90 μl of growth medium. 4 Cells were resuspended in 5% CO2 solution. An 8-point dose response of bi-Fab-MMAE was prepared in growth media at 5x the final assay concentration, with a maximum final concentration of 30 nM. 10 μl of the bi-Fab-MMAE dose set was pipetted into a 384-well plate, with each concentration tested in duplicate wells. 40 μl of cells were pipetted into the wells, and the plate was incubated at 37° C., 5% CO2 for 96 hours. After incubation, 5 μl of MTS reagent was pipetted into each well, and the plate was incubated for an additional 3 hours at 37° C., 5% CO2. Absorbance was read at 492 nm and 690 nm. OD690 nm was subtracted from OD492 nm, and data was plotted using GraphPad PRISM software.
[0140] [Table 6]
[0141] result The determined cytotoxicity of each conjugated bispecific antibody tested on the full cell line panel, along with the fold selectivity of each construct for double positive CD33+ / CD7+ cell lines compared to CD33+ / CD7- or CD33- / CD7+ cell lines, is shown in Table 5. From these results, BVX130 was selected for further analysis due to the strong cytotoxicity seen in CD33+ / CD7+ cell lines and the increased fold selectivity seen against CD33+ / CD7- and CD33- / CD7+ cell lines.
[0142] Cytotoxic activity of BVX100 and BVX130MMAF conjugates in CD7 single positive cell lines reagent Jurkat cells DSMZ282 LOUCY cells DSMZ394 BVX130-MMAF (P01-32, 10.5μM) In-house - Head of Chemistry BVX100-MMAF (193-15, 13 μM) In-house - Head of Chemistry BSA (Bovine Serum Albumin Fraction V 100ml 7.5% Catalog No. 15260037) ThermoFisher PBS / A (Catalog number 50086470) VWR Corning 384-well clear flat bottom polystyrene TC-treated microplate SLS alamarBlue™ Cell Viability Reagent (DAL1025) ThermoFisher RPMI-1640 medium 21875034 Gibco, LifeTechnologies GlutaMAX™ Nutritional Supplement 35050061 Gibco, a LifeTechnologies company Fetal bovine serum, heat inactivated 10500064 Gibco, LifeTechnologies Penicillin-Streptomycin (10,000U / mL) 15140122 Gibco, LifeTechnologies
[0143] method Jurkat and LOUCY cell lines were harvested and counted, and the amount needed to seed 2000 cells per well across 100 wells in 40 μl of medium per well was calculated for a 384-well plate. A 10-point dose response of BVX130-MMAF and BVX100-MMAF was prepared in assay medium (RPMI, 10% FBS, 1% Glutamax, 1% Pen / Strep) at 5x the final concentration, with a top final concentration of 30 nM. 10 μl of each dose was pipetted into triplicate wells of a 384-well plate, with a separate plate for each cell line tested. 500,000 cells from each cell line were pipetted into 5 ml of assay medium and the cells were pelleted. Each cell pellet was resuspended in 10 ml of assay medium and 40 μl was pipetted into the indicated wells. 50 μl of assay medium was pipetted into blank control wells and 50 μl of PBS was pipetted into all spare wells and the plate was incubated for 4 days at 37° C., 5% CO2. After 4 days of incubation, 5 μl of Alamar Blue reagent was added per well and the plate was read after further incubations of 4 and 6 hours at 37° C., 5% CO2. Data for each reading was plotted in GraphPad PRISM and IC50 values were recorded.
[0144] result The affinity-regulated CD33+ / CD7+ bispecific antibody BVX130 conjugated to an MMAF or MMAE cytotoxic payload has reduced cytotoxicity in CD7 single antigen positive cells compared to BVX100, as seen in Figures 7 to 9.
[0145] As shown, CD33+ / CD7+ bispecific antibodies conjugated to a cytotoxic payload induce robust cytotoxicity in immortalized CD33+ / CD7+ cell lines (Figures 3 to 6). In CD33+ / CD7- cell lines (Table 5) and cell lines expressing CD33- / CD7+ (Figures 7 to 9), reduced cytotoxicity was observed in constructs with low affinity CD7 binding arms and high affinity CD33 binding arms. This is also true when two different cytotoxic payloads are conjugated to the bispecific antibody. This suggests that CD33+ / CD7+ bispecific antibodies conjugated to a cytotoxic payload can be used to induce robust cytotoxicity in CD33+ / CD7+ cells while reducing cytotoxicity in CD33 and CD7 single antigen positive cells such as monocytes (CD33+ / CD7-) and T cells (CD33- / CD7+).
[0146] The constructs BVX102, BVX152, BVX162, BVX110, BVX120, and BVX130 all show promise as therapeutic agents, with BVX130 in particular showing similar activity to BVX110 and BVX120.
[0147] The described embodiments are not intended to limit the scope of protection afforded by the claims, but rather to illustrate examples of how the invention may be practiced. Sequence Listing
[0148] CD7-PP-1-WT CD7 binding arm sequence: VH:
[0149] [ka]
[0150] VH CDR1:
[0151] [ka]
[0152] VH CDR2:
[0153]
change
[0154] VH CDR3:
[0155]
change
[0156] VL:
[0157]
change
[0158] VL CDR1:
[0159]
change
[0160] VL CDR2:
[0161]
change
[0162] VL CDR3:
[0163]
change
[0164] Relock:
[0165]
change
[0166] Light chain:
[0167] [ka]
[0168] CD7-PP-2 CD7 binding arm sequence: VH:
[0169] [ka]
[0170] VH CDR1:
[0171] [ka]
[0172] VH CDR2:
[0173] [ka]
[0174] VH CDR3:
[0175] [ka]
[0176] VL:
[0177] [ka]
[0178] VL CDR1:
[0179] [ka]
[0180] VL CDR2:
[0181] [ka]
[0182] VL CDR3:
[0183] [ka]
[0184] Heavy Chain:
[0185] [ka]
[0186] Light chain:
[0187] [ka]
[0188] CD7-PP-3 CD7 binding arm sequence: VH:
[0189] [ka]
[0190] VH CDR1:
[0191] [ka]
[0192] VH CDR2:
[0193] [ka]
[0194] VH CDR3:
[0195] [ka]
[0196] VL:
[0197] [ka]
[0198] VL CDR1:
[0199] [ka]
[0200] VL CDR2:
[0201] [ka]
[0202] VL CDR3:
[0203] [ka]
[0204] Heavy Chain:
[0205] [ka]
[0206] Light chain:
[0207] [ka]
[0208] CD7-PP-6 binding sequence: VH:
[0209]
change
[0210] VH CDR1:
[0211]
change
[0212] VH CDR2:
[0213]
change
[0214] VH CDR3:
[0215]
change
[0216] VL:
[0217]
change
[0218] VL CDR1:
[0219]
change
[0220] VL CDR2:
[0221]
change
[0222] VL CDR3:
[0223] [ka]
[0224] Heavy Chain:
[0225] [ka]
[0226] Light chain:
[0227] [ka]
[0228] CD7-PP-7 CD7 binding arm sequence: VH:
[0229] [ka]
[0230] VH CDR1:
[0231] [ka]
[0232] VH CDR2:
[0233] [ka]
[0234] VH CDR3:
[0235] [ka]
[0236] VL:
[0237] [ka]
[0238] VL CDR1:
[0239] [ka]
[0240] VL CDR2:
[0241] [ka]
[0242] VL CDR3:
[0243] [ka]
[0244] Heavy Chain:
[0245] [ka]
[0246] Light chain:
[0247] [ka]
[0248] CD7-PP-8 CD7 binding arm sequence: VH:
[0249] [ka]
[0250] VH CDR1:
[0251]
change
[0252] VH CDR2:
[0253]
change
[0254] VH CDR3:
[0255]
change
[0256] VL:
[0257]
change
[0258] VL CDR1:
[0259]
change
[0260] VL CDR2:
[0261]
change
[0262] VL CDR3:
[0263]
change
[0264] Heavy Chain:
[0265] [ka]
[0266] Light chain:
[0267] [ka]
[0268] CD7-PP-12 CD7 binding arm sequence: VH:
[0269] [ka]
[0270] VH CDR1:
[0271] [ka]
[0272] VH CDR2:
[0273] [ka]
[0274] VH CDR3:
[0275] [ka]
[0276] VL:
[0277] [ka]
[0278] VL CDR1:
[0279] [ka]
[0280] VL CDR2:
[0281] [ka]
[0282] VL CDR3:
[0283] [ka]
[0284] Heavy Chain:
[0285] [ka]
[0286] Light chain:
[0287] [ka]
[0288] CD7-PP-13 CD7 binding arm sequence: VH:
[0289] [ka]
[0290] VH CDR 1:
[0291] [ka]
[0292] VH CDR 2:
[0293]
change
[0294] VH CDR 3:
[0295]
change
[0296] VL:
[0297]
change
[0298] VL CDR1:
[0299]
change
[0300] VL CDR2:
[0301]
change
[0302] VL CDR3:
[0303]
change
[0304] Relock:
[0305]
change
[0306] Lock:
[0307]
change
[0308] CD33-PP-1-WT binding peptide sequence: VH:
[0309]
change
[0310] VH CDR 1:
[0311]
change
[0312] VH CDR 2:
[0313]
change
[0314] VH CDR 3:
[0315]
change
[0316] VL:
[0317]
change
[0318] VL CDR 1:
[0319]
change
[0320] VL CDR 2:
[0321]
change
[0322] VL CDR 3:
[0323]
change
[0324] CD33-PP-4 binding sequence: VH:
[0325]
change
[0326] VH CDR 1:
[0327]
change
[0328] VH CDR 2:
[0329]
change
[0330] VH CDR 3:
[0331]
change
[0332] VL:
[0333]
change
[0334] VL CDR 1:
[0335]
change
[0336] VL CDR 2:
[0337]
change
[0338] VL CDR 3:
[0339]
change
[0340] CD33-PP-7 binding sequence: VH:
[0341]
change
[0342] VH CDR 1:
[0343]
change
[0344] VH CDR 2:
[0345]
change
[0346] VH CDR 3:
[0347]
change
[0348] VL:
[0349] [ka]
[0350] VL CDR 1:
[0351] [ka]
[0352] VL CDR 2:
[0353] [ka]
[0354] VL CDR 3:
[0355] [ka]
[0356] Optional signal sequence upstream of the VH and VL domains
[0357] [ka]
Claims
1. A bispecific antibody or antigen-binding fragment thereof that binds to CD33 and CD7, array: VH SEQ ID NO: 81 and VL SEQ ID NO:85 a first binding region that binds to human CD33, comprising a sequence having at least 95% sequence identity to a second binding region that binds to human CD7, comprising VH CDR1, VH CDR2, VH CDR3 of SEQ ID NO: 31, and VL CDR1, VL CDR2, VL CDR3 of SEQ ID NO: 35, the sequences being defined by the IMGT numbering system; A bispecific antibody or an antigen-binding fragment thereof comprising:
2. The sequence of the first binding region that binds to human CD33 is the sequence: VH SEQ ID NO: 81 and VL SEQ ID NO:85 The bispecific antibody or antigen-binding fragment thereof of claim 1, having at least 98%, 99% or 100% sequence identity to
3. 3. The bispecific antibody or antigen-binding fragment thereof according to claim 1 or 2, wherein the second binding region that binds to human CD7 comprises a VH sequence comprising SEQ ID NO: 31, or a sequence having 95% sequence identity thereto, and a VL sequence comprising SEQ ID NO: 35, or a sequence having 95% sequence identity thereto.
4. 4. A pharmaceutical composition for use in the treatment of CD7+CD33+ hematological malignancies, comprising a bispecific antibody or an antigen-binding fragment thereof according to any one of claims 1 to 3.
5. The pharmaceutical composition of claim 4, wherein the bispecific antibody or antigen-binding fragment thereof is capable of inducing internalization into CD33+ and / or CD7+ cells via CD33 and / or CD7 receptors.
6. The pharmaceutical composition of claim 4 or 5, wherein the CD33+ and CD7+ cells are AML cells.
7. The pharmaceutical composition of claim 5 or 6, wherein the bispecific antibody or antigen-binding fragment thereof is capable of mediating antibody-dependent cellular cytotoxicity.
8. The pharmaceutical composition of claim 5 or 6, wherein the bispecific antibody or antigen-binding fragment thereof is bound to or formed with an immune effector cell, and optionally, the immune effector cell comprises a T cell and / or a NK cell.
9. 9. The pharmaceutical composition of claim 8, wherein the immune effector cell is a bispecific anti-CD33 anti-CD7 CAR-T.
10. The pharmaceutical composition of claim 9, wherein the T cells comprise CD33+ T cells, CD7+ T cells, or a combination thereof.
11. The pharmaceutical composition of claim 4 or 5, wherein the bispecific antibody or antigen-binding fragment thereof comprises i) a cell-killing portion, ii) a CD7-binding portion, and iii) a CD33-binding portion.
12. The pharmaceutical composition of claim 11 , wherein the CD33 binding portion comprises an antigen-binding fragment of an antibody and / or the CD7 binding portion comprises an antigen-binding fragment of an antibody.
13. 13. The pharmaceutical composition of claim 12, wherein the cell-killing moiety is a cytotoxin, optionally wherein the cytotoxin is selected from i) a peptide toxin or ii) a chemical toxin.
14. The pharmaceutical composition of claim 12 or 13, wherein the bispecific antibody or antigen-binding fragment thereof further comprises a linking moiety linking the cell-killing moiety to the CD7-binding moiety and / or the CD33-binding moiety.
15. The pharmaceutical composition of any one of claims 12 to 14, wherein the bispecific antibody or antigen-binding fragment thereof is in the form of an antibody-drug conjugate.
